Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21NO3.ClH |
Molecular Weight | 347.836 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]12OC3=C4C(C[C@H]5N(CC=C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3O
InChI
InChIKey=NAHATSPWSULUAA-ZQGPYOJVSA-N
InChI=1S/C19H21NO3.ClH/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20;/h2-6,12-13,15,18,21-22H,1,7-10H2;1H/t12-,13+,15-,18-,19-;/m0./s1
Molecular Formula | C19H21NO3 |
Molecular Weight | 311.3749 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://en.medicine-cure.com/ovr4_nalorfin.htmCurator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_12280.html | https://www.ncbi.nlm.nih.gov/pubmed/16433932 | https://www.ncbi.nlm.nih.gov/pubmed/6301606 | doi:10.3181/00379727-77-18904
Sources: http://en.medicine-cure.com/ovr4_nalorfin.htm
Curator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_12280.html | https://www.ncbi.nlm.nih.gov/pubmed/16433932 | https://www.ncbi.nlm.nih.gov/pubmed/6301606 | doi:10.3181/00379727-77-18904
Nalorphine has a mixed opioid agonist-antagonist properties. Nalorphine inhibits the cholinesterases of mouse brain, bovine erythrocytes and horse serum. It acts on mu-, k- and sigma-opioid receptors. Nalorfin by virtue of the agonistic effect has an analgesic effect but to a much lesser extent than morphine. Initially, before the appearance of a "pure" morphine-naloxone antagonist, nalorphine was used as an antidote for severe respiratory depression and other body function disorders caused by acute poisoning in case of an overdose of morphine, promedol, fentanyl or other narcotic analgesics, or with increased sensitivity to them. At present, nalorphine is practically not used for this purpose. It was replaced by naloxone. Large doses of nalorphine can cause nausea, cramps, drowsiness, headache, mental stimulation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3198 Sources: doi: 10.3181/00379727-77-18904 |
|||
Target ID: CHEMBL4329 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16433932 |
1.6 nM [Ki] | ||
Target ID: CHEMBL270 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8819494 |
|||
Target ID: CHEMBL3602 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6301606 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Norfin Approved UseIt is used as an antidote for opiates. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.12 μg/g |
2 mg/kg single, subcutaneous dose: 2 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
NALORPHINE unknown | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.17 μg × h/g |
2 mg/kg single, subcutaneous dose: 2 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
NALORPHINE unknown | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23 min |
2 mg/kg single, subcutaneous dose: 2 mg/kg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
NALORPHINE unknown | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: http://en.medicine-cure.com/ovr4_nalorfin.htm
Adults appoint 0,005 - 0,01 g (1 - 2 ml of a 0.5% solution). If the effect is insufficient, the injections are repeated at intervals of 10 to 15 minutes. The total dose should not exceed 0.04 g (8 ml of 0.5% solution).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8819494
Maximum stimulation of [35S]GTPyS binding by Nalorphine using a single saturating concentration of ligand (10 uM) was compared with stimulation by DAAMGO (10 uM). Intrinsic activity determined for Nalorphine in C6 glioma cells was 9%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:52 GMT 2023
by
admin
on
Fri Dec 15 15:00:52 GMT 2023
|
Record UNII |
9FPE56Z2TW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
||
|
CFR |
21 CFR 522.1452
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9FPE56Z2TW
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
57-29-4
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
100000085689
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
200-321-8
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
DBSALT001652
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
1452002
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
m7716
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID3047847
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
SUB03381MIG
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL415284
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
C76849
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY | |||
|
5484366
Created by
admin on Fri Dec 15 15:00:52 GMT 2023 , Edited by admin on Fri Dec 15 15:00:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |